Both sodium–glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk of cardiovascular events, mortality, hospitalisation for heart failure and adverse kidney outcomes in individuals with type 2 diabetes at very high cardiorenal risk (i.e. with a history of CVD, heart failure or kidney disease), independent of their glucose-lowering effects [6, 7]. Here, SLC5A2 is linked to heart failure.